A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing - Remitting multiple sclerosis (TIME MS)

Gina M. Remington, Katherine Treadaway, Teresa Frohman, Amber Salter, Olaf Stüve, Michael K. Racke, Kathleen Hawker, Federica Agosta, Maria Pia Sormani, Massimo Filippi, Elliot M. Frohman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral MMF in multiple sclerosis (MS). Methods: Twenty-four treatment-naá»ve Rg-RMS patients participated in a one-year prospective, placebo-controlled, blinded, safety pilot clinical trial. Every patient injected weekly intramuscular interferon beta-1a. The cohort was then randomized (1 : 1) to either active oral MMF or identical-appearing placebo tablets. Clinical evaluations were assessed every 3 months, along with brain MRI scans performed at baseline and repeated every 60 days for one year. Comprehensive laboratory assessments were monitored for safety, along with adverse events. Results: In this small pilot investigation, no differences were identified between the two treatment groups with respect to patient-reported adverse events, MRI metrics, or laboratory abnormalities. Notwithstanding these observations, and the limited number of patients treated, trends appeared to favor the combination therapy regimen. Conclusions: The combination treatment regimen of interferon beta-1a and MMF appeared to be well tolerated in this pilot study. Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of MMF in MS appears warranted.

Original languageEnglish
Pages (from-to)3-13
Number of pages11
JournalTherapeutic Advances in Neurological Disorders
Volume3
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Mycophenolic Acid
Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis
Placebos
Safety
Therapeutics
Nucleic Acid Synthesis Inhibitors
Sample Size
Tablets
Interferon beta-1a
B-Lymphocytes
Macrophages
Magnetic Resonance Imaging
Clinical Trials
T-Lymphocytes
Brain

Keywords

  • CellCept
  • Immunosuppression
  • Mycophenolate mofetil
  • Relapsing-remitting multiple sclerosis
  • Treatment naá»ve

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Pharmacology

Cite this

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing - Remitting multiple sclerosis (TIME MS). / Remington, Gina M.; Treadaway, Katherine; Frohman, Teresa; Salter, Amber; Stüve, Olaf; Racke, Michael K.; Hawker, Kathleen; Agosta, Federica; Sormani, Maria Pia; Filippi, Massimo; Frohman, Elliot M.

In: Therapeutic Advances in Neurological Disorders, Vol. 3, No. 1, 01.2010, p. 3-13.

Research output: Contribution to journalArticle

Remington, Gina M. ; Treadaway, Katherine ; Frohman, Teresa ; Salter, Amber ; Stüve, Olaf ; Racke, Michael K. ; Hawker, Kathleen ; Agosta, Federica ; Sormani, Maria Pia ; Filippi, Massimo ; Frohman, Elliot M. / A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing - Remitting multiple sclerosis (TIME MS). In: Therapeutic Advances in Neurological Disorders. 2010 ; Vol. 3, No. 1. pp. 3-13.
@article{fd7a7935abfa43e5ae0747086fdf3771,
title = "A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing - Remitting multiple sclerosis (TIME MS)",
abstract = "Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral MMF in multiple sclerosis (MS). Methods: Twenty-four treatment-na{\'a}»ve Rg-RMS patients participated in a one-year prospective, placebo-controlled, blinded, safety pilot clinical trial. Every patient injected weekly intramuscular interferon beta-1a. The cohort was then randomized (1 : 1) to either active oral MMF or identical-appearing placebo tablets. Clinical evaluations were assessed every 3 months, along with brain MRI scans performed at baseline and repeated every 60 days for one year. Comprehensive laboratory assessments were monitored for safety, along with adverse events. Results: In this small pilot investigation, no differences were identified between the two treatment groups with respect to patient-reported adverse events, MRI metrics, or laboratory abnormalities. Notwithstanding these observations, and the limited number of patients treated, trends appeared to favor the combination therapy regimen. Conclusions: The combination treatment regimen of interferon beta-1a and MMF appeared to be well tolerated in this pilot study. Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of MMF in MS appears warranted.",
keywords = "CellCept, Immunosuppression, Mycophenolate mofetil, Relapsing-remitting multiple sclerosis, Treatment na{\'a}»ve",
author = "Remington, {Gina M.} and Katherine Treadaway and Teresa Frohman and Amber Salter and Olaf St{\"u}ve and Racke, {Michael K.} and Kathleen Hawker and Federica Agosta and Sormani, {Maria Pia} and Massimo Filippi and Frohman, {Elliot M.}",
year = "2010",
month = "1",
doi = "10.1177/1756285609355851",
language = "English",
volume = "3",
pages = "3--13",
journal = "Therapeutic Advances in Neurological Disorders",
issn = "1756-2856",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing - Remitting multiple sclerosis (TIME MS)

AU - Remington, Gina M.

AU - Treadaway, Katherine

AU - Frohman, Teresa

AU - Salter, Amber

AU - Stüve, Olaf

AU - Racke, Michael K.

AU - Hawker, Kathleen

AU - Agosta, Federica

AU - Sormani, Maria Pia

AU - Filippi, Massimo

AU - Frohman, Elliot M.

PY - 2010/1

Y1 - 2010/1

N2 - Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral MMF in multiple sclerosis (MS). Methods: Twenty-four treatment-naá»ve Rg-RMS patients participated in a one-year prospective, placebo-controlled, blinded, safety pilot clinical trial. Every patient injected weekly intramuscular interferon beta-1a. The cohort was then randomized (1 : 1) to either active oral MMF or identical-appearing placebo tablets. Clinical evaluations were assessed every 3 months, along with brain MRI scans performed at baseline and repeated every 60 days for one year. Comprehensive laboratory assessments were monitored for safety, along with adverse events. Results: In this small pilot investigation, no differences were identified between the two treatment groups with respect to patient-reported adverse events, MRI metrics, or laboratory abnormalities. Notwithstanding these observations, and the limited number of patients treated, trends appeared to favor the combination therapy regimen. Conclusions: The combination treatment regimen of interferon beta-1a and MMF appeared to be well tolerated in this pilot study. Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of MMF in MS appears warranted.

AB - Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral MMF in multiple sclerosis (MS). Methods: Twenty-four treatment-naá»ve Rg-RMS patients participated in a one-year prospective, placebo-controlled, blinded, safety pilot clinical trial. Every patient injected weekly intramuscular interferon beta-1a. The cohort was then randomized (1 : 1) to either active oral MMF or identical-appearing placebo tablets. Clinical evaluations were assessed every 3 months, along with brain MRI scans performed at baseline and repeated every 60 days for one year. Comprehensive laboratory assessments were monitored for safety, along with adverse events. Results: In this small pilot investigation, no differences were identified between the two treatment groups with respect to patient-reported adverse events, MRI metrics, or laboratory abnormalities. Notwithstanding these observations, and the limited number of patients treated, trends appeared to favor the combination therapy regimen. Conclusions: The combination treatment regimen of interferon beta-1a and MMF appeared to be well tolerated in this pilot study. Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of MMF in MS appears warranted.

KW - CellCept

KW - Immunosuppression

KW - Mycophenolate mofetil

KW - Relapsing-remitting multiple sclerosis

KW - Treatment naá»ve

UR - http://www.scopus.com/inward/record.url?scp=77953453035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953453035&partnerID=8YFLogxK

U2 - 10.1177/1756285609355851

DO - 10.1177/1756285609355851

M3 - Article

C2 - 21180632

AN - SCOPUS:77953453035

VL - 3

SP - 3

EP - 13

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

SN - 1756-2856

IS - 1

ER -